Renin-Angiotensin System as a Therapeutic Target for Colorectal Cancer Liver Metastasis

Authors

  • Muluken Altaye Ayza Department of Pharmacology and Toxicology, College of Health Sciences, Mekelle, Ethiopia
  • B Khalid Department of Pharmacology and Toxicology, College of Health Sciences, Mekelle, Ethiopia

DOI:

https://doi.org/10.37591/rrjooh.v7i2.374

Abstract

Classically, renin-angiotensin system (RAS), for a long time, has been perceived as the main regulator of cardiovascular homeostasis, due to its effect on blood vessels contraction or cardiac hypertrophy and is known to maintain blood pressure and body fluids. Hence, its pharmacological regulation is mainly associated with the management of hypertension. Currently, it was found that the RAS is involved in a broad range of physiological processes and diseases. RAS can induce physiological and pathological responses related to cancer biology, including tumor growth, cell proliferation, apoptosis, angiogenesis, and inflammation, indicating the main cellular transduction processes activated by main RAS pathways. This review focuses on the role of RAS in cancer and its role in the liver regeneration for patients with colorectal cancer liver metastasis.

 

Keywords: Renin-angiotensin system, colorectal cancer, liver regeneration

Cite this Article

Muluken AA, Khalid B. Renin-Angiotensin System as a Therapeutic Target for Colorectal Cancer Liver Metastasis. Research & Reviews: Journal of Oncology & Hematology. 2018; 7(2): 1–14p.

Author Biography

  • Muluken Altaye Ayza, Department of Pharmacology and Toxicology, College of Health Sciences, Mekelle, Ethiopia
    department of pharmacology and toxicology, assistant lecturer

Downloads

Published

2018-09-14

Issue

Vol. 7 No. 2 (2018)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.